Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections.

Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC.
Journal   J Infect Dis.
Species  
Analytes Measured   IgG
Matrix Tested   Serum
Year   2012
Volume   206
Page Numbers   915-923
Application   Immunogenicity
Abstract
BACKGROUND: Staphylococcus aureus has numerous virulence factors, including exotoxins that may increase the severity of infection. This study was aimed at assessing whether preexisting antibodies to S. aureus toxins are associated with a lower risk of sepsis in adults with S. aureus infection complicated by bacteremia.

METHODS: We prospectively identified adults with S. aureus infection from 4 hospitals in Baltimore, MD, in 2009–2011. We obtained serum samples from prior to or at presentation of S. aureus bacteremia to measure total immunoglobulin G (IgG) and IgG antibody levels to 11 S. aureus exotoxins. Bacterial isolates were tested for the genes encoding S. aureus exotoxins using polymerase chain reaction (PCR).

RESULTS: One hundred eligible subjects were included and 27 of them developed sepsis. When adjusted for total IgG levels and stratified for the presence of toxin in the infecting isolate as appropriate, the risk of sepsis was significantly lower in those patients with higher levels of IgG against α-hemolysin (Hla), δ-hemolysin (Hld), Panton Valentine leukocidin (PVL), staphylococcal enterotoxin C-1 (SEC-1), and phenol-soluble modulin α3 (PSM-α3).

CONCLUSIONS: Our results suggest that higher antibody levels against Hla, Hld, PVL, SEC-1, and PSM-α3 may protect against sepsis in patients with invasive S. aureus infections.

View Publications

Related Products

ELISA Conversion Pack I (uncoated plates)
IgG
Singleplex
Cell Based Assays Development Pack
IgG
Singleplex
V-PLEX SARS-CoV-2 Panel 6 (IgG) Kit
SARS-CoV-2 N, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike, SARS-CoV-2 Spike (B.1.1.7), SARS-CoV-2 Spike (B.1.351), SARS-CoV-2 Spike (D614G), SARS-CoV-2 Spike (P.1) | Human
Multiplex
V-PLEX COVID-19 Coronavirus Panel 2 (IgG) Kit
HCoV-229E Spike, HCoV-HKU1 Spike, HCoV-NL63 Spike, HCoV-OC43 Spike, SARS-CoV-1 Spike, SARS-CoV-2 N, SARS-CoV-2 S1 NTD, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike | Human
Multiplex
V-PLEX COVID-19 Respiratory Panel 3 (IgG) Kit
Flu A/Hong Kong/2014 H3, Flu A/Michigan/2015 H1, Flu A/Shanghai/2013 H7, Flu B/Brisbane/2008 HA, Flu B/Phuket/2013 HA, HCoV-229E Spike, HCoV-HKU1 Spike, HCoV-NL63 Spike, HCoV-OC43 Spike, MERS-CoV Spike, RSV Pre-Fusion F, SARS-CoV-1 Spike, SARS-CoV-2 N, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike | Human
Multiplex
V-PLEX COVID-19 Respiratory Panel 2 (IgG) Kit
Flu A/Hong Kong/2014 H3, Flu A/Michigan/2015 H1, Flu A/Shanghai/2013 H7, Flu B/Brisbane/2008 HA, Flu B/Phuket/2013 HA, HCoV-229E Spike, HCoV-HKU1 Spike, HCoV-NL63 Spike, HCoV-OC43 Spike, RSV Pre-Fusion F, SARS-CoV-1 Spike, SARS-CoV-2 N, SARS-CoV-2 S1 NTD, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike | Human
Multiplex
V-PLEX COVID-19 Coronavirus Panel 3 (IgG) Kit
HCoV-229E Spike, HCoV-HKU1 Spike, HCoV-NL63 Spike, HCoV-OC43 Spike, MERS-CoV Spike, SARS-CoV-1 Spike, SARS-CoV-2 N, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike | Human
Multiplex
V-PLEX SARS-CoV-2 384 Panel 1 (IgG) Kit
SARS-CoV-2 N, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike | Human
Multiplex
V-PLEX SARS-CoV-2 Panel 1 (IgG) Kit
SARS-CoV-1 Spike, SARS-CoV-2 N, SARS-CoV-2 S1 NTD, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike | Human
Multiplex
V-PLEX SARS-CoV-2 Panel 2 (IgG) Kit
SARS-CoV-2 N, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike | Human
Multiplex
V-PLEX Respiratory Panel 1 (IgG) Kit
Flu A/Hong Kong/2014 H3, Flu A/Michigan/2015 H1, Flu A/Shanghai/2013 H7, Flu B/Brisbane/2008 HA, Flu B/Phuket/2013 HA, RSV Pre-Fusion F | Human
Multiplex
Isotyping Panel 1 Human/NHP Kit
IgA, IgG, IgM | Human, Non-human primate
Multiplex
Human/NHP IgG Kit
IgG | Human, Non-human primate
Singleplex
SULFO-TAG Anti-Human IgG Antibody, 5 Plate
IgG | Human
Browse Our Products

By Analytes
By Applications
Search
Meso Scale Japan 株式会社